pocketful logo light
pocketful logo light
Sun Pharmaceutical Industries Ltd logo

Sun Pharmaceutical Industries Ltd

NSE: SUNPHARMA BSE: 524715

₹1958

(0.08%)

Wed, 29 Jul 2026, 11:32 pm

mtf coin illustrationMTF 5x

Sun Pharmaceutical Industries Share Price Live Chart

1 Day

(0.08%)

No Result Found

Summary

  • Market Cap (in Cr)

    432096.23

  • Net Profit (in Cr)

    10980.1

  • P/B

    5.77

  • Sector P/E

    33.76

  • P/E

    38.10

  • EV/EBITDA

    24.60

  • Debt/Equity (Industry)

    0.16

  • Interest Cover (Industry)

    17.01

  • ROCE (Industry)

    16.41

  • RONW (Industry)

    14.52

  • ROE

    16.16

  • ROCE

    19.52

  • Debt/Equity

    0.04

  • EPS (TTM)

    52.01

  • Dividend Yield

    0.89

  • Book Value

    348.31

  • Interest Cover

    60.44

Analysis

No Result Found

Read More

Financials

Read More

Ratios

Read More

Shareholding

ShareholdersMAR 2026DEC 2025SEPT 2025JUN 2025MAR 2025
Promoters54.4854.4854.4854.4854.48
FII15.9416.1216.5517.2617.96
DII21.1120.8220.2319.5018.70
Public8.488.588.738.778.87
Government0.000.000.000.000.00

Read More

Technical Analysis

RSI

68.43

MACD

30.71

50 DMA

1872.56

200 DMA

1769.63

Support and Resistance

TypeR3R2R1PPS1S2S3
Classic2131.771986.171924.331840.571778.731694.971549.37
Fibonacci1986.171930.551896.191840.571784.951750.591694.97
Camarilla1902.541889.191875.851840.571849.151835.811822.46

Pivots Level: Classic

R3

+291.20

2131.77

R2

+145.60

1986.17

R1

+83.77

1924.33

1840.57
1840.57
Pivot Point
LTP: 1989.90

S1

-61.83

1778.73

S2

-145.60

1694.97

S3

-291.20

1549.37

Moving Average

SMAEMA

Period

Value

  • 10-EMA

    1959.10

  • 20-EMA

    1936.08

  • 30-EMA

    1916.11

  • 50-EMA

    1885.09

  • 100-EMA

    1836.27

  • 200-EMA

    1787.52

Read More

Corporate Actions

Announcement DatePurposeActionEx Date
22 May 2026board-meetingsAccounts, Final Dividend
31 Jan 2026dividend₹11.00 Dividend /Share05 Feb 2026
31 Jan 2026board-meetingsQuarterly Results, Interim Dividend
05 Jan 2026dividendInterim Dividend - Rs. - 1105 Feb 2026
05 Nov 2025board-meetingsQuarterly Results
07 Jun 2025dividendFinal Dividend - Rs. - 5.507 Jul 2025
22 May 2025agm
22 May 2025dividend₹5.50 Dividend /Share07 Jul 2025
31 Jan 2025dividend₹10.50 Dividend /Share06 Feb 2025
06 Jan 2025dividendInterim Dividend - Rs. - 10.506 Feb 2025

Read More

Peer Comparison

Sun Pharmaceutical Industries Ltd logo

Sun Pharmaceutical Industries Ltd

Cipla Ltd logo

Cipla Ltd

Dr Reddys Laboratories Ltd logo

Dr Reddys Laboratories Ltd

Torrent Pharmaceuticals Ltd logo

Torrent Pharmaceuticals Ltd

Zydus Lifesciences Ltd logo

Zydus Lifesciences Ltd

Divis Laboratories Ltd logo

Divis Laboratories Ltd

Read More

Sun Pharmaceutical Industries Ltd About

Sun Pharmaceuticals Industries is engaged in the business of manufacturing developing and marketing a wide range of branded and generic formulation and Active Pharmaceutical ingredients (APIs). The Company has various manufacturing locations spread across the country with trading and other incidental and related activities extending to the global market.

Industry

Pharmaceuticals - Indian - Bulk Drugs & Formln

Founded

1993

Headquarters

CEO

Dilip S Shanghvi

Employees

Contact

Website icon

Website

http://www.sunpharma.com

Email icon

Email

secretarial@sunpharma.com

Phone icon

Phone

91-265-6615500

Location icon

Location

Sun Pharma Advanced Res.Centre, Tandalja, Vadodara, Gujarat, 390020

Read More

Sun Pharmaceutical Industries Ltd Company History

YearHistory
2020
  • Launched FluGuard (Favipiravir) in India at Rs. 35 per tablet.
  • Introduced ABSORICA LD Capsules for severe recalcitrant nodular acne in the US.
2021
  • Launched website for Long Term Care Portfolio in the US.
  • Launched Sunkalp on National Doctors' Day.
  • Launched Chericof 12 in India for 12-hour cough relief.
2022
  • Entered license agreement with SPARC for commercialization of phenobarbital for injection in the US.
  • Expanded license and supply agreements with Cosmo for WINLEVI to include Japan.
  • Launched CEQUA, first dry eye treatment with nanomicellar technology, in Canada.
  • Obtained exclusive patent license from Lundbeck to introduce Vortioxetine in India.
  • Acquired Uractiv Portfolio from Fiterman Pharma in Romania.
2023
  • Entered licensing agreement with Zydus for co-marketing Desidustat in India.
  • US FDA accepted NDA filing for Deuruxolitinib.
  • Sun Pharma Canada launched PR WINLEVI (clascoterone cream 1% w/w) for acne.
  • Entered licensing agreement with Pharmazz Inc. for Tyvalzi (Sovateltide) in India.
  • Launched nationwide initiative Second Birth Date on National Doctor’s Day.
2024
  • Entered global exclusive commercialization, license, and supply agreement with Philogen for FIBROMUN.
  • Completed acquisition of all outstanding shares of Taro.
  • Included in S&P Global Sustainability Yearbook.
  • Launched STARIZO (Tedizolid Phosphate) in India for acute bacterial skin and skin structure infections.

Read More

Deals

Client NameDeal TypeOrder SideQTYAvg PriceDate
GQG PARTNERS EMERGING MARKETS EQUITY CITblockBuy14464141763.918 Nov 2025
RELIANCE TRUST INSTITUTIONAL RETIREMENT TRUST SERIES TWELVEblockSell14464141763.918 Nov 2025
GOLDMAN SACHS BANK EUROPE SE - ODIblockBuy1482331631.609 Oct 2025
GOLDMAN SACHS (SINGAPORE) PTE - ODIblockSell1482331631.609 Oct 2025
THE MTBJ LTD. AS TRST FOR GOVRNMNT PENSION INVSTMNT FUND MTBJ400045828blockSell309391167214 Jul 2025
THE MTBJ LTD.AS TRST FOR GOVERNMENT PENSION INVESTMENT FUND MTBJ400045849blockBuy309391167214 Jul 2025
THE JUPITER GLOBAL FUND-JUPITER INDIA SELECTblockBuy6562861556.9527 Feb 2024
JUPITER SOUTH ASIA INVESTMENT COMPANY LIMITEDblockSell6562861556.9527 Feb 2024
BNP PARIBAS ARBITRAGEblockSell32538961382.125 Jan 2024
MARSHALL WACE INVESTMENT STRATEGIES MARKET NEUTRAL TOPS FUNDblockBuy1277121382.125 Jan 2024

Read More

Sun Pharmaceutical Industries Ltd News

Sun Pharma wins Brazil nod for semaglutide

Sun Pharmaceutical Industries Limited has secured regulatory approval from Brazil's ANVISA to manufacture and market semaglutide for type 2 diabetes. The company plans a rapid launch with partner Hypera Pharma in the USD 413 million market.

29 Jul 2026

companies

Sun Pharma Sees ₹198.88 Cr NSE Block Trade

Sun Pharmaceutical recorded a block trade on NSE worth ₹198.88 crores, involving approximately 1,003,116 shares at ₹1982.60 per share.

28 Jul 2026

equity-markets

Philogen Re-Submits NIDLEGY™ Application to EMA

Sun Pharmaceutical's partner Philogen has re-submitted the NIDLEGY™ marketing application to the European Medicines Agency for the treatment of advanced melanoma.

27 Jul 2026

companies

Sun Pharma Sees ₹438.09 Cr Block Trade on NSE

Sun Pharmaceutical recorded a block trade of ₹438.09 crores on the NSE, involving approximately 2,242,462 shares at a price of ₹1953.60 per share.

27 Jul 2026

equity-markets

Sun Pharma Sees ₹39.91 Cr Block Trade on NSE

Sun Pharmaceutical Industries recorded a block trade of ₹39.91 crores on the NSE, involving approximately 204,378 shares at a price of ₹1952.60 per share.

27 Jul 2026

equity-markets

Read More

Open Your Free Demat Account

Enter your phone number